Square Pharmaceuticals PLC. (DSE:SQURPHARMA)
Bangladesh
· Delayed Price · Currency is BDT 209.30
-3.10 (-1.46%)
At close: May 13, 2025
DSE:SQURPHARMA Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 70,101 | 60,708 | 57,598 | 50,703 | 45,876 | Upgrade
|
| Revenue Growth (YoY) | 15.47% | 5.40% | 13.60% | 10.52% | 4.18% | Upgrade
|
| Cost of Revenue | 37,957 | 32,473 | 28,719 | 25,470 | 23,141 | Upgrade
|
| Gross Profit | 32,144 | 28,235 | 28,879 | 25,233 | 22,736 | Upgrade
|
| Selling, General & Admin | 14,168 | 11,689 | 12,118 | 10,034 | 8,855 | Upgrade
|
| Other Operating Expenses | -199.9 | -144.4 | -98.27 | -69.57 | 10.79 | Upgrade
|
| Operating Expenses | 13,968 | 11,545 | 12,019 | 9,965 | 8,865 | Upgrade
|
| Operating Income | 18,176 | 16,690 | 16,860 | 15,269 | 13,870 | Upgrade
|
| Interest Expense | -244 | -118.97 | -0.03 | -0.01 | -0.11 | Upgrade
|
| Interest & Investment Income | 4,651 | 3,957 | 3,004 | 3,137 | 2,965 | Upgrade
|
| Earnings From Equity Investments | 2,595 | 2,523 | 2,011 | 1,291 | 586.24 | Upgrade
|
| Currency Exchange Gain (Loss) | 346.52 | 650.1 | 451.34 | 19.42 | -0.7 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 34.43 | 33.62 | Upgrade
|
| EBT Excluding Unusual Items | 25,524 | 23,701 | 22,325 | 19,751 | 17,455 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 384.59 | 177.04 | 100.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | -208 | -79.8 | 53.49 | - | 28.38 | Upgrade
|
| Other Unusual Items | 0.26 | 0.62 | 0.72 | 32.06 | - | Upgrade
|
| Pretax Income | 25,316 | 23,622 | 22,764 | 19,960 | 17,583 | Upgrade
|
| Income Tax Expense | 4,389 | 4,642 | 4,607 | 4,013 | 4,229 | Upgrade
|
| Earnings From Continuing Operations | 20,927 | 18,980 | 18,157 | 15,947 | 13,354 | Upgrade
|
| Minority Interest in Earnings | -1.61 | -0.24 | 0.03 | - | - | Upgrade
|
| Net Income | 20,926 | 18,980 | 18,157 | 15,947 | 13,354 | Upgrade
|
| Net Income to Common | 20,926 | 18,980 | 18,157 | 15,947 | 13,354 | Upgrade
|
| Net Income Growth | 10.25% | 4.53% | 13.86% | 19.42% | 5.60% | Upgrade
|
| Shares Outstanding (Basic) | 886 | 886 | 886 | 886 | 886 | Upgrade
|
| Shares Outstanding (Diluted) | 886 | 886 | 886 | 886 | 886 | Upgrade
|
| EPS (Basic) | 23.61 | 21.41 | 20.48 | 17.99 | 15.06 | Upgrade
|
| EPS (Diluted) | 23.61 | 21.41 | 20.48 | 17.99 | 15.06 | Upgrade
|
| EPS Growth | 10.25% | 4.53% | 13.86% | 19.42% | 5.60% | Upgrade
|
| Free Cash Flow | 14,348 | 5,685 | 6,692 | 7,178 | 8,718 | Upgrade
|
| Free Cash Flow Per Share | 16.18 | 6.41 | 7.55 | 8.10 | 9.84 | Upgrade
|
| Dividend Per Share | 11.000 | 10.500 | 10.000 | 6.000 | 4.476 | Upgrade
|
| Dividend Growth | 4.76% | 5.00% | 66.67% | 34.04% | 19.74% | Upgrade
|
| Gross Margin | 45.85% | 46.51% | 50.14% | 49.77% | 49.56% | Upgrade
|
| Operating Margin | 25.93% | 27.49% | 29.27% | 30.11% | 30.23% | Upgrade
|
| Profit Margin | 29.85% | 31.26% | 31.52% | 31.45% | 29.11% | Upgrade
|
| Free Cash Flow Margin | 20.47% | 9.37% | 11.62% | 14.16% | 19.00% | Upgrade
|
| EBITDA | 20,495 | 19,000 | 18,695 | 17,151 | 15,791 | Upgrade
|
| EBITDA Margin | 29.24% | 31.30% | 32.46% | 33.83% | 34.42% | Upgrade
|
| D&A For EBITDA | 2,319 | 2,310 | 1,835 | 1,882 | 1,921 | Upgrade
|
| EBIT | 18,176 | 16,690 | 16,860 | 15,269 | 13,870 | Upgrade
|
| EBIT Margin | 25.93% | 27.49% | 29.27% | 30.11% | 30.23% | Upgrade
|
| Effective Tax Rate | 17.34% | 19.65% | 20.24% | 20.10% | 24.05% | Upgrade
|
| Revenue as Reported | - | - | 57,598 | 50,703 | 45,876 | Upgrade
|
| Advertising Expenses | 1,355 | 961.42 | 3.61 | 3.01 | 8.7 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.